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Abstract 
Apoptotic death pathways are frequently activated by death ligand induction and 
subsequent activation of the membrane proximal signaling module. Death receptors 
cluster upon binding to death ligands, leading to formation of a membrane proximal 
death-inducing-signaling-complex (DISC). In this membrane proximal signalosome, 
initiator caspases (caspase 8) are processed resulting in activation of both type 1 and type 
2 pathways of apoptosis signaling. How the type 1/type 2 choice is made is an important 
question in the systems biology of apoptosis signaling. In this study, we utilize a Monte 
Carlo based in silico approach to elucidate the role of membrane proximal signaling 
module in the type 1/type 2 choice of apoptosis signaling. Our results provide crucial 
mechanistic insights into the formation of DISC signalosome and caspase 8 activation. 
Increased concentration of death ligands was shown to correlate with increased type 1 
activation. We also study the caspase 6 mediated system level feedback activation of 
apoptosis signaling and its role in the type 1/type 2 choice. Our results clarify the basis of 
cell-to-cell stochastic variability in apoptosis activation and ramifications of this issue is 
further discussed in the context of therapies for cancer and neurodegenerative disorders.  
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Introduction 
Apoptosis, a programmed mode of cell death, is used in a variety of cellular and 
physiological situations ranging from developmental regulations to tissue homeostasis. 
Apoptosis is frequently mediated by death ligands (DL) that are known to cluster death 
receptors (DR) and membrane proximal adaptor proteins in a signaling complex called 
DISC (death inducing signaling complex). Procaspase 8 is recruited by adaptor molecules 
in the DISC and gets cleaved to its active form caspase 8, which in turn, activates both 
type 1 and type 2 pathways of apoptosis. However, a clear mechanistic understanding of 
DISC formation and caspase 8 activation, under death ligand induction, is lacking. In 
addition to its relevance in the biology of apoptosis, such mechanistic understanding can 
be key to developing therapies for apoptosis related diseases. Death ligand (such as FasL) 
induced apoptosis has been shown to be the mode of cell death in activation induced cell 
death (ADCC) in lymphocytes (Elmore 2007). In addition, killing of pathogen infected 
cells or tumor cells by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells is 
frequently mediated by death ligands (Elmore 2007). TRAIL, a death ligand found on the 
plasma membrane of NK cells (Takeda et al. 2001), has emerged as a promising agent in 
cancer chemotherapy (Falschlehner et al. 2007; Shirley et al. 2011; Kurita et al. 2011; 
Picarda et al. 2012). Recent experiments have shown that the fraction of melanoma (skin 
cancer) stem cells is much higher in NOD SCID IL2rg-/- mice than that found in regular 
NOD SCID xenotransplantation assays (Quintana et al. 2008). Mice lacking the IL2rg 
receptor chain are known to be depleted of NK cells, thus, indicating an important role 
for TRAIL mediated killing of tumor cells. DISC formation and Caspase 8 activation 
have also been implicated in neurodegenerative disorders such as in Alzheiemer’s disease 
where Aβ (amyloid beta) oligomers and aggregates provide the apoptotic stimuli (Picone 
et al. 2009; Di Carlo 2010). In addition to apoptosis, death receptor activation has been 
shown to be involved in other forms of cell death such as necrosis and necroptosis (Kim 
et al. 2000; Daniels et al. 2005). 
Death ligand induction leads to caspase 8 activation and thus could activate both type 1 
and type 2 pathways. Understanding the mechanisms of type 1/type 2 regulation remains 
an important problem in the biology of apoptosis. Some of the initial experiments 
classified cells as either type 1 or type 2 depending on their mode of activation (Scaffidi 
et al. 1998; Scaffidi et al. 1999). It was indicated that DISC formation and caspase 8 
activation is stronger in type 1 cells (Scaffidi et al. 1998). Even though initial studies 
found that increased caspase 8 activation can switch the activation from type 2 to type 1 
(Scaffidi et al. 1998; Hua et al. 2005), a clear mechanistic understanding of such a 
correlation was lacking as caspase 8 molecules activate both type 1 and type 2 pathways 
(Okazaki et al. 2008). Crucial insight into the problem can be provided by considering the 
kinetic rate constants for reactions involving caspase 8 with its immediate binding 
partners in type 1 and type 2 pathways. Preferential binding of capsase 8 with Bid (type 2 
pathway) explains the type 2 phenotype in cells exhibiting low caspase 8 activation 
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(Raychaudhuri et al. 2008; Raychaudhuri and Raychaudhuri 2013). The levels of initiator 
caspases (pro-caspase 8 and pro-caspase 9) have also been shown to be key regulators of 
the type 1/ type 2 choice (Okazaki et al. 2008). In a previous work, we have shown that 
type 1/type 2 choice is regulated at a systems level (Raychaudhuri and Raychaudhuri 
2013). How fast the activation signal propagates through the type 1 and type 2 pathways, 
to finally activate effector caspases (caspase 3/7), was shown to determine the type 1/type 
2 choice. Therefore, it becomes clear that both caspase 8 activation and systems level 
regulation downstream of caspase 8 activation determine the type 1/type 2 choice. Even 
though an important regulatory role of active caspase 8 in the type 1/type 2 choice has 
been established, the mechanism of caspase 8 activation (such as by death ligand 
induction) remains to be clearly elucidated. In this context, one may ask whether 
concentration of death ligands can impact the type 1/type 2 choice in apoptosis signaling. 
One also needs to consider the effect of inherent state of the membrane proximal module 
on the type 1/type 2 choice. Due to its crucial role in the regulatory mechanisms of 
apoptosis signaling, the question of type 1/ type 2 choice has important ramifications for 
cancer and neurodegenerative disorders. We have recently studied the possibility of 
switching the activation from type 2 to type 1 by targeting the membrane proximal 
apoptotic signaling module in cancer cells (Raychaudhuri and Raychaudhuri 2013). 
Recent experiments also explored how a type 2 to type 1 transition can be achieved in the 
context of TRAIL induced apoptosis (Kurita et al. 2011). The problem of type 1/type 2 
choice also has important ramifications for neurodegenerative disorders such as in 
Alzheimer's disease. Aggregated form of Aβ peptides were shown to activate the type 1 
pathway of apoptosis, whereas Aβ oligomers mainly activated the type 2 pathway 
(Picone et al. 2009). Caspase 8 activation was observed under the action of both Aβ 
oligomers and aggregates (even though Aβ oligomers may enter the cytosol and mediate 
its dominant apoptotic effect). Therefore, a mechanistic understanding of the activation of 
the membrane proximal signaling module and its role in the type 1/type 2 choice, during 
apoptotic activation, can have profound implications for therapies for cancer and 
neurodegenerative disorders.     
 
Activation of the membrane proximal apoptotic module, hence the type 1/type 2 choice, 
is further impacted by a systems level feedback mechanism mediated by caspase 6. It is 
known that active caspase 3 can proteolytically cleave pro-caspase 6 and generate active 
caspase 6 molecules. Caspase 6 has effector activities (similar to other effector caspases 
such as caspase 3/7) but they are also capable of activating caspase 8. Thus caspase 8 
activation, upon death ligand induction, can propagate the activation signal through the 
type 1/type 2 loop network finally leading to activation of caspase 3 -> caspase 6 -> 
caspase 8 in a systems level feedback loop (Figure 1). Here, we study the effect of 
caspase 6 mediated feedback activation and elucidate the role of caspase 6 on the type 
1/type 2 choice. Caspase 6 has attracted much recent attention in the context of neural 
cell apoptosis neurodegenerative disorders (Leblanc 2013). However, activation of 
caspase 6 in some of these cases might be through non-canonical pathways (different 
from the usual caspase 8 -> caspase 3 -> caspase 6 activation).      
Cell-to-cell variability in apoptosis signaling has been established as an important 
regulatory mechanism in apoptotic cell death (Raychaudhuri et al. 2008; Raychaudhuri 
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2010; Albeck et al. 2008; Dussmann et al. 2010; Lee et al. 2010). Expression levels of 
pro- and anti-apoptotic proteins are usually cell-type specific (Lopez-Araiza et al. 2006), 
but significant cell-to-cell variability (within a population of a given cell type) in protein 
levels has been observed (Spencer et al. 2009). Such cellular variability in apoptotic 
molecules can generate single cell variability in apoptotic activation (Spencer et al. 2009; 
Skommer et al. 2010). However, even when all the cellular parameters are identical, cell-
to-cell variability can result from inherently stochastic signaling reactions (Raychaudhuri 
et al. 2008; Raychaudhuri 2010; Skommer et al. 2010). Interestingly, cell-to-cell inherent 
variability can have important implications for diseases in which apoptosis is 
dysregulated (Raychaudhuri et al. 2010; Skommer et al. 2010; Brittain et al. 2010; 
Skommer et al. 2011a; Skommer et al. 2011b). In a recent work, we have shown that low 
probability activation of Bax by BH3 only activators (such as Bid) is a mechanism for 
generating cell-to-cell variability (Raychaudhuri and Das 2013). We have also found that 
cell-to-cell variability in this situation is remarkably sensitive to the Bcl-2 to Bax ratio 
(Bcl2 to Bax ratio > 1 was linked to slow apoptotic activation with cell-to-cell stochastic 
variability). In cancer cells, high Bcl2 to Bax ratio is frequently observed and is a 
mechanism for apoptosis resistance of cancer cells (Certo et al. 2006). In contrast, in 
Alzheimer's diseases a recent study has shown that the Bcl2 to Bax ratio (to < 1) can be 
altered by Aβ peptides to favor apoptotic activation, which can then be reversed by the 
application of brain-derived neurotrophic factors (BDNF) to protect neural cells (Sun et 
al. 2012). Therefore, novel chemotherapeutic strategies (in cancer and neurodegenerative 
disorders) might be possible to design that would rely on modulating cell-to-cell 
stochastic variability in apoptotic activation. Our previous works have indicated that the 
problem of type 1/type 2 choice is linked to the issue of cell-to-cell stochastic variability 
in apoptosis (as activation through the type 2 pathway is frequently associated with 
stochastic variability while type 1 activation remains deterministic) (Raychaudhuri et al. 
2008; Raychaudhuri and Raychaudhuri 2013). Hence, elucidating the role of death 
ligands and the membrane proximal signaling module in the type 1/type 2 choice can 
have major implications for understanding cell-to-cell stochastic variability in apoptosis 
activation and also for apoptosis related diseases.         
In this work, we develop a hybrid Monte Carlo (MC) simulation to study the question of 
type 1/type 2 choice in apoptosis activation. Specifically, we address how the following 
parameters impact the type 1/type 2 choice: (1) concentration of death ligands and (2) the 
inherent state of the membrane proximal module. Our results indicate increased death 
ligand concentration increases type 1 activation and may lead to a type 2 to type 1 
transition for a given cell type. The expression levels of pro- and anti-apoptotic proteins 
in the membrane proximal signaling module are also shown to be crucial in caspase 8 
activation and the type 1/type 2 choice. Our study provides mechanistic insights into the 
process of DISC clustering and caspase 8 activation (upon induction of death ligands). In 
addition, we consider the systems level feedback mechanism mediated by caspase 6 
activation and elucidates its role on type 1/type 2 choice. We discuss the implications of 
our results for cell-to-cell stochastic variability in apoptotic activation and show how 
such stochastic variability can be utilized to design therapies for cancer and 
neurodegenerative disorders.      
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Methods 
The signaling model for apoptotic cell death 
We carried out a computational study of death ligand induced apoptosis using Monte 
Carlo (MC) simulations. A simplified network model of apoptotic death signaling (Figure 
1) was studied utilizing controlled in silico experiments. Both type 1 and type 2 pathways 
were simulated.  
In our model, casapse 8 (initiator caspase) activation initiates signaling through both type 
1 and type 2 pathways. Death ligands (such as FasL / TRAIL) undergo binding / 
unbinding reactions with death receptors with nanomolar affinity. Probability parameters 
Pon and Poff  are used to simulate binding / unbinding between death ligands and receptors 
(those presumably vary depending on the receptor type). Ligand binding supposedly 
induces a conformational change in the death receptors leading to their oligomerization 
(Scott et al. 2009). In our model, two ligand bound death receptors reduce their free 
energy (Edd is taken to be -2 KBT unless specified otherwise) when occupying 
neighboring lattice sites and thus induce clustering of death receptors. Adaptor proteins 
(such as FADD / TRADD for Fas receptors) could bind to ligand bound death receptors, 
with moderately high 108 M-1 affinity, using an interaction between their death domains 
(DD). Affinity for this receptor-adaptor interaction was assumed to be similar to that 
between the adaptor molecule and pro-caspase 8. Adaptor molecules could also bind to 
free death receptors albeit with a low probability (affinity ~ 1 M-1) so that significant 
apoptotic activation does not occur without ligand induction. Death effector domains 
(DED) of the adaptor molecules are known to bind with the DED domains of pro-caspase 
8 molecules (kon: 3.5 × 106 M-1 s-1 and koff: 0.018 s-1) (Hua et al. 2005). However, this 
interaction takes place only when adaptors are already bound to death receptors. 
Therefore, ligand binding could induce clustering of death receptors and recruitment of 
adaptor molecules to clustered death receptors. Procaspase 8 molecules are then recruited 
to the clustered adaptor proteins to generate the assembly of DISC (death-inducing-
signaling-complex), ultimately leading to active caspase 8 molecules through 
autoprocessing (Peter and Krammer 2003). In this work, DISC formation was simulated 
using a hybrid simulation scheme between kinetic Monte Carlo model for signaling 
reactions with an explicit free energy based model for the clustering of death receptors 
(Raychaudhuri 2013).  
Active caspase 8 initiates signaling through both type 1 and type 2 pathways. In the type 
1 pathway, caspase 8 directly processes procaspase 3 (effector caspases) to generate 
active caspase 3. In the type 2 pathway, caspase 8 cleaves Bid to an active form (tBid) 
which translocates to mitochondria to bind with Bax. We have earlier shown that higher 
affinity of active caspase 8 for Bid, compared with that for pro-caspase 3, leads to 
preferential activation of the type 2 pathway (at early times) (Raychaudhuri and 
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Raychaudhuri 2013). Additional complexities, in the initial type 1/type 2 choice, might 
arise from cell type specific rate of Bid cleavage (such as due to Bid phosphorylation 
status in a given cell type) (Ozoren and El-Deiry 2002), but are not considered here. 
When two Bax molecules are bound to tBid (on the mitochondrial membrane) they could 
detach as an active Bax dimer. Apoptotic inhibitor Bcl2 molecules bind with tBid and 
Bax and thereby inhibit formation of active Bax dimers. It is also possible for Bid to 
directly activate Bax albeit with a low probability (Raychaudhuri and Das 2013). 
Cytochrome c is released into the cytosol in an all-or-none manner when the number of 
active Bax dimers reaches a pre-assigned threshold value (Goldstein et al. 2000; 
Dussmann et al. 2010). Cytochrome c release leads to cytochorme c-Apaf binding and the 
subsequent formation of multi-molecular cyto c-Apaf-ATP complex apoptosome. 
Formation of the apoptosome complex is modeled in a simplified manner (by a cyto c-
Apaf-Apaf-cyto c complex) where Apaf represents the Apaf-ATP complex. In our Monte 
Carlo simulations, effective low probability of apoptosome formation generates 
stochastic variability in apoptotic activation, but once formed, induces rapid activation of 
downstream caspases 9 and 3 (Raychaudhuri et al. 2008; Lee et al. 2010; Bagci et al. 
2006). Caspase 9 is an initiator caspase (similar to caspase 8), which gets activated in the 
clustered assembly of apoptosome (whereas caspase 8 gets activated in DISC). The 
CARD domain of pro-caspase 9 interacts with the Apaf CARD domain (Sheridan et al. 
1997; Pan et al. 1997; Mantovani et al. 2001). Active caspase 9, in turn, cleaves 
procaspase 3 to its active form caspase 3. Apoptotic inhibitor XIAP binds to procaspase 
9, caspase 9, and caspase 3 using its BIR domains (Riedl et al. 2001; Shiozaki et al. 
2003), thus it could inhibit apoptotic activation in both type 1 and type 2 pathways. 
However, the release of mitochondrial Smac can antagonize the inhibition of XIAP 
(Huang et al. 2003; Sun et al. 2002). Smac is released simultaneously with cytochrome c 
in an all-or-none type manner. Active Caspase 3 can process pro-caspase 6 to 
proteolytically active caspase 6, another effector caspase but it also has the ability to 
activate pro-caspase 8 (Sun et al. 2002). Thus caspase 6 provides a systems level 
feedback loop for both type1 and type 2 apoptotic activation. The details of all the 
reaction moves that are downstream of caspase 8 and considered in our current 
simulation (of the apoptosis pathway) are provided in our earlier works (Raychaudhuri 
and Raychaudhuri 2013). Activation of caspase 3 (effector caspase) closes the type 1/type 
2 activation loop (that is initiated by active caspase 8) and thus can be taken to be a 
downstream readout of apoptotic cell death signaling; MC simulations were carried out to 
measure the time-course of caspase activation at a single cell level.  
Even though the present model can capture some of the essential systems level regulatory 
mechanisms of the apoptotic signaling pathway, it has several simplifying assumptions. 
In our model, effects of functionally similar proteins are coarse-grained by a 
representative protein. Bcl-2 (B cell lymphoma protein 2), for example, represents all the 
Bcl-2 family proteins (such as Bcl-2, Bcl-xL, Mcl-1) with similar anti-apoptotic 
properties. In this context, it should be noted that the death receptors / ligands simulated 
here capture the effect of only one type of receptor / ligand (such as Fas / FasL or DR4 / 
TRAIL), not the combined effect of all the death receptors / ligands. In our present study, 
DISC formation has been modeled in a simplified manner. Different isoforms of cFLIP 
have been implicated in differential regulation of apoptotic activation (Safa and Pollok 
2011; Fricker et al. 2010). A role of cleavage product of cFLIP (such as p43-FLIP) in 
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NF-kB activation has also been studied using mathematical modeling (Neumann et al. 
2010). Here, we consider only the anti-apoptotic action of cFLIP (such as by cFLIPs that 
competitively binds with adaptor proteins in the DISC signalosome). In our study, the 
threshold of apoptotic activation, such as the threshold death ligand needed to trigger 
apoptosis, is governed by the level of apoptotic inhibitors such as cFLIP, Bcl2 and XIAP. 
In addition, the rate of synthesis and degradation of signaling molecules (such as 
caspases) can modify the threshold of activation (Gu et al. 2011) but is not considered 
here.   
 
Monte Carlo Simulation of Cell Death Signaling  
Monte Carlo approach has been shown to capture some of the complexities of signaling 
reactions such as the effect of spatial heterogeneity (Raychaudhuri 2013). Each run of our 
Monte Carlo simulation corresponds to apoptotic activation in a single cell, thus, Monte 
Carlo can capture cell-to-cell stochastic variability including inherent variability. We 
utilize a hybrid Monte Carlo simulation scheme that combines the following approaches: 
(1) a probabilistic rate constant based (implicit free energy) kinetic Monte Carlo 
simulation for various reaction moves such as diffusion, binding/unbinding and catalytic 
cleavage; (2) an explicit free-energy based model that captures clustering of ligand-bound 
death receptors utilizing energy-function based diffusion moves. Both of the above 
approaches have been utilized in previous works from this lab (Raychaudhuri 2013). At 
each Monte Carlo (MC) step molecules are randomly sampled N number of times, where 
N is the total number of molecules (either free or complexed) present in the system. 
Therefore, at each Monte Carlo (MC) step, one molecule is sampled (on average) once to 
allow for either diffusion or a reaction move. All the intracellular reaction moves 
(considered in our current simulations) and the corresponding kinetic rate constants can 
be found in our earlier works. Diffusion moves are carried out to one of the randomly 
chosen neighboring sites (4 for membrane bound molecules and 6 for cytosolic 
molecules) provided the condition of mutual physical exclusion is satisfied. In the kinetic 
Monte Carlo part of the simulation, once a diffusion/reaction move is randomly sampled 
it is accepted only if a randomly generated number in [0,1] is less than the pre-defined 
probability constant for that particular move (otherwise the move is rejected). The 
detailed balance condition is satisfied through the ratio Pon/Poff, the probability constants 
for the binding and unbinding reactions, respectively (Raychaudhuri 2013). In the explicit 
free energy based part of the simulation, diffusion moves are accepted based on 
Metropolis criterion (Paccept = min[1,exp(-ΔE/KBT)], where ΔE is the free energy 
difference between the new and the previous configuration (Newman and G.T. 1999).  
 
Estimation of Parameter Values (used in Our Monte Carlo Simulation)  
A simulation volume of 1.2 × 1.2 × 1.2 µm3 (corresponding to a 60 × 60 × 60 lattice with 
lattice spacing Δx ~20 nm) is chosen in such a manner that the number of molecules (for 
each molecular species) is equal to the nanomolar concentration. Death receptors are 
placed on one surface of the simulation lattice (1.2 × 1.2 µm2); death ligands are placed 
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on a surface parallel to the surface on which death receptors are placed. Cytochrome 
c/Smac is initially contained in a mitochondrial volume of 0.36 × 0.36 × 0.36 µm3 (18 × 
18 × 18 lattice). Utilization of a small system size significantly reduces the computational 
cost of the simulation. Each MC step (ΔT) is chosen to be 10-4 s based on known mobility 
of cytosolic molecules. This allows us to take the probability of diffusion (Pdiff) for the 
fastest diffusing species (cytosolic molecules) to a value 0.5 (an approximate diffusion 
constant can be estimated D ~ (1/2) × Pdiff ×  (Δx)2/(ΔT) ~  (1/2) × 0.5 × (Δx)2/(ΔT) ~  1 
µm2/s). Consistent with lower diffusion constants known for membrane proteins, 
probability of diffusion for molecules on the plasma membrane (or the mitochondrial 
membrane) is taken an order of magnitude lower than that is used for cytosolic 
molecules. It is reasonable to expect that the multi-molecular complex apoptosome will 
have significantly reduced mobility and its Pdiff is assumed to be zero. Kinetic reaction 
rates (such as kon/koff) and molecular concentrations are obtained from values reported in 
the literature (mostly from (Hua et al. 2005)) and utilized in our previous work 
(Raychaudhuri et al. 2008; Raychaudhuri and Das 2013; Raychaudhuri and Raychaudhuri 
2013) (unless specified otherwise). Even though Hua et al. considered activation by Fas 
ligands, the binding affinities for other death receptor-ligands are known to be similar (in 
the nano-molar range). Probabilistic reaction rate constants used in this study are 
obtained from kinetic rate constants using a previously described parameter-mapping 
scheme (Raychaudhuri 2013). Poff (or Pcatalysis) simulation parameters are obtained by 
multiplying koff (or kcatalysis) values by 10-4 s (1 MC time-step). Probabilistic parameters 
for association reactions are determined using the following relation: Pon = 102 × kon nM-1 
s-1 (Raychaudhuri 2013). A typical simulation is run for 2 × 108 MC steps. Controlled 
Monte Carlo experiments are carried out for specific parameter values (such as molecular 
concentrations). Each run of the simulation corresponds to activation at a single cell 
level. We define the following parameters for quantitatively assessing the extent of type 1 
and type 2 activations: Ntype1/( Ntype1 + Ntype2) and Ntype2/( Ntype1 + Ntype2), where Ntype1 and 
Ntype2 represents the number of active caspase 3 molecules generated by caspase 8 and 
caspase 9, respectively.   
 
 
Results 
Expression levels of death receptor and other molecules in the membrane proximal 
signaling module are key determinants of the type 1/type 2 choice in apoptosis 
Expression levels of death receptors (DRs), death adaptor proteins, apoptotic procaspase 
8 and anti-apoptotic cFLIP define the inherent state of the membrane proximal signaling 
module. Death ligand induction perturbs the membrane proximal module leading to 
clustering of death receptors and adaptor proteins in the form of DISC and subsequent 
activation of caspase 8. We first consider the effect of variation in death receptor 
concentration on apoptotic activation keeping other molecules (including the ones in the 
membrane module) fixed. Death receptor expression is known to be cell type specific 
though cell-to-cell variability in death receptor level can be significant (Meng et al. 
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2011). The cell-type specific variability in death receptor expression has recently been 
shown to be a regulator of the type 1/type 2 choice in apoptotic death signaling (Meng et 
al. 2011). Here, we explore the mechanistic basis of the observed correlation between 
death receptor expression and the type 1/type 2 choice in apoptosis signaling. We studied 
apoptotic activation as the number of death receptors was varied in the following manner: 
2, 10 and 100 molecules. Death ligand concentration was kept constant at 10 molecules in 
these simulations. In Fig. 2 we show the fraction of type 1 activation which increased 
with increasing expression of death receptor levels. Consistent with this, the time-to-
death (averaged over 60 single cells) decreased with increasing level of death receptors: 
Td = 1.08 × 108  MC steps for DR = 2, Td =  0.73 × 108  MC steps for DR = 10 and Td =  
0.72 × 108  MC steps for DR = 100. Type 1 cells are known to have high death receptor 
expression (SKW 6.4 has ~225 molecules/µm2 and H9 has ~190 molecules/µm2) (Meng 
et al. 2011). In our simulation, type 1 activation was observed for lower concentration of 
death receptors (than found in typical type 1 cells), but we simulate an effective 
expression of death receptors and some of the anti-apoptotic factors, such as the 
expression of decoy receptors (Pan et al. 1997), are not explicitly considered. In addition, 
lipid mediated interactions and other complexities of DISC formation may modify the 
type 1/type 2 choice. However, increased type 1 activation with increasing expression of 
death receptor levels, as observed in our in silico studies, should be robust. In our 
simulations, increased death receptor expression led to more rapid and increased 
generation of active caspase 8 molecules (Fig. 2) and thereby increased type 1 signaling. 
Previous studies including that carried out in this lab have indicated a key role of active 
caspase 8 molecules in the type 1/type 2 choice (Scaffidi et al. 1998; Hua et al. 2005; 
Raychaudhuri et al. 2008; Raychaudhuri and Raychaudhuri 2013). However, strong 
caspase 8 activation may not always lead to type 1 activation as, for example, type 2 
signaling has been observed in caspase 3 deficient MCF-7 cell line despite significant 
active caspase 8 generation in those cells (Scaffidi et al. 1998).  
Consistent with our earlier findings (Raychaudhuri et al. 2008; Raychaudhuri and 
Raychaudhuri 2013), type 2 activation was accompanied by large cell-to-cell stochastic 
variability (Fig 3a). Interestingly, cell-to-cell variation in the caspase 8 activation (within 
a cell population) provides a mechanism for generating cell-to-cell stochastic variability 
in apoptosis, especially when the death receptor concentration is low (~ 2 molecules) (Fig 
3b). Clearly, cell-to-cell variability in caspase 8 activation contributes to cell-to-cell 
variability in effector caspase activation. In Fig. 3c, we show that the time to initial 
caspase 3 (10% of total) activation, at the level of single cells, is correlated with the 
initiation of caspase 8 activation.     
It is reasonable to expect that the inherent state of the membrane proximal signaling 
module is cell type specific and combined effect of all the molecules in the membrane 
module impact the type 1/ type 2 choice. In our simulations, we varied the number of 
molecules in the membrane proximal signaling module in the following manner: (1) 
FADD = 10, cFLIP = 10 and procaspase 8 = 10, (2) FADD = 100, cFLIP = 100 and 
procaspase 8 = 100 and (3) FADD = 100, cFLIP = 10 and procaspase 8 = 100. 
Concentrations of both death ligands and death receptors were kept constant at 10 
molecules. In our simulations, FADD represents the adaptor proteins that bind to both 
death receptor and intracellular signaling molecules such as pro-caspase 8 (see Methods). 
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In Fig. 4, we show the type 1 fraction of activation as the membrane proximal signaling 
module is varied. Increased type 1 activation correlated well with increased DISC 
formation and generation of active caspase 8 molecules (Scaffidi et al. 1998). The time-
to-death decreased with increasing type 1 activation: Td = 4.3 × 107  MC steps for FADD 
= 10, cFLIP = 10, procaspase 8 = 10; Td =  3.9 × 107 MC steps or FADD = 100, cFLIP = 
100, procaspase 8 = 100 and Td =  1.4 × 107 MC steps for FADD = 100, cFLIP = 10, 
procaspase 8 = 100.   
In our simulations, increased cFLIP level (or the cFLIP/procaspase 8 ratio) led to reduced 
level of active caspase 8 generation resulting in decreased apoptosis and increased type 2 
signaling. When we simulated Jurkat T cell (leukemia cell line) parameters obtained in 
(Hua et al. 2005), type 2 signaling dominated apoptotic activation. However, when cFLIP 
level was inhibited, there was marked increase in type 1 activation. Increased cFLIP level 
has been observed in certain cancer cells and also been correlated with cancer 
chemoresistance (Safa and Pollok 2011). However, when cFLIP level was low but FADD 
and procaspase 8 levels were high, fast and robust type 1 activation was observed in our 
simulations (Fig 4). Thus it might be possible to induce strong apoptotic activation in 
cancer cells, by application of death ligands, when cFLIP level is low (or inhibited) but 
other molecules in the membrane module are robustly expressed.   
 
Increase in death ligand concentration increases type 1 activation and crucially 
regulates the type 1/type 2 choice  
Concentration of death ligands presumably varies in vivo and the effect of such 
concentration variation needs to be studied in a systematic manner. We carried out 
controlled in silico experiments where the concentration of death ligands was varied 
keeping all other parameters constant. Death ligand concentration was varied in the 
following manner: 2, 10 and 100 molecules. For each of these death ligand 
concentrations the level of death receptor was varied in a similar manner: 2, 10 and 100 
molecules.  We observed that increased level of death ligand induction led to enhanced 
type 1 activation (Fig 5). When both death ligand and death receptor concentrations were 
high, rapid deterministic activation of the type 1 pathway has been observed. However, 
for low level of death ligand induction (~ 1-2 molecules), apoptotic activation was 
dominated by the type 2 pathway with large cell-to-cell variability (Fig. 6). Therefore, 
even in cells that are known as type 1 cells (equipped with high level of death receptor 
expression) it might be possible to alter the signaling phenotype from type 1 to type 2 by 
decreasing the death ligand concentration (Especially when the interaction between death 
domains of the death receptor and the adaptor molecule is high affinity with Kd ~ 10 nM 
(Miyazaki and Reed 2001)). In a similar manner, large amount of death ligand induction 
might increase type 1 activation in type 2 cells. However, in type 2 cells having very low 
expression of death receptors, such as hepatocytes (Meng et al. 2011), it becomes 
difficult to activate the type 1 pathway and activation of a second initiator caspase 
(caspase 9) becomes essential for robust activation of effector caspases. For type 2 cells 
equipped with very low death receptor expression it might still be possible to activate the 
type 1 pathway in the following manner: (1) when the type 2 pathway is blocked 
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resulting in a slow type 1 activation, (2) by enhancing expression of pro-apoptotic 
membrane molecules especially the death receptor expression (Meng et al. 2011), (3) by 
inhibiting anti-apoptotic proteins such as cFLIP or XIAP (Jost et al. 2009; Raychaudhuri 
and Raychaudhuri 2013). Other cell-type specific mechanisms for type 2 to type 1 
transition are possible, such as, removing sequestration of c-MET bound Fas receptors by 
application of HGF (hepatocyte growth factors) (Accordi et al. 2007) or enhancing the 
expression of caspase 3 in caspase 3 deficient cell line MCF-7 (Scaffidi et al. 1998).  
Therefore, it seems reasonable to expect that both type 1 and type 2 pathways can get 
activated irrespective of cell types.     
It is expected that death ligand concentration and the inherent state of the membrane 
module would regulate the clustering of DISC and thereby govern caspase 8 activation. 
The parameter (Edd) governing the free-energy reduction of two neighboring death-ligand 
bound receptors should also be a regulator of DISC generation. Varying this free-energy 
parameter, resulted in altered clustering of death receptors and DISC generation. The 
effect of death ligand concentration on the type 1 / type 2 choice is frequently mediated 
by variation in death receptor clustering and DISC generation. Increased clustering was 
observed in the case of high death ligand level (100 molecules), which seems to correlate 
well with activation of caspase 8 (Supplemental Fig. 1). The effect of increased death 
ligand concentration on receptor clustering was more pronounced when the free energy 
parameter Edd = -3 KBT (Supplemental Fig. 1b). As mentioned earlier (Methods section), 
Edd is an effective parameter and may vary depending on the cell type. In addition, it 
might be possible to enhance Edd (Legembre et al. 2005; Thome et al. 2012) selectively in 
cancer cells and induce apoptosis by death ligand induction or generating DISC 
formation by some other mechanisms.  
Caspase 6 provides a system level feedback loop for apoptotic pathways and thereby 
impacts the type 1/type 2 choice 
Caspase 8 activation initiates signaling through the type 1 and type 2 pathways ultimately 
resulting in activation of effector caspases (caspase 3/7), thus creating a loop network 
structure at the systems level. Caspase 6 is another effector caspase that is activated by 
active caspase 3, but once activated it could also activate caspase 8 providing a 
mechanism for systems level feedback regulation. It is expected that a significant amount 
of active caspase 3 will be utilized to carry out their effector functions and only a fraction 
of it will be available for processing pro-caspase 6. We do not explicitly model the 
effector activities of active caspase 3, instead, a lower rate effective rate constant is 
assumed for caspase 3 activation of caspase 6. In our simulations, the rate constants for 
binding (Pon: between caspase 3 and pro-caspase 6) and catalytic activation (Pcat: 
generation of active caspase 6 from caspase3-pro-caspase 6 complex) were taken to be 
0.1 times that was used for caspase 3 activation by caspase 9. Similar rate constants were 
assumed for binding and catalytic activation for caspase 6 – pro-caspase 8 reaction. It is 
reasonable to expect that, similar to active caspase3, a significant portion of active 
caspase 6 will engage its effector substrates (such as lamin A) resulting in effective lower 
rate constants for its activation of caspase 8.   
Caspase 6 activation led to increased generation of active caspase 8 molecules and thus 
favored the type 1 activation. In Fig 7a, we show the type 1 fraction of activation for two 
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different combinations of death ligand and death receptor concentrations, with and 
without caspase 6. When both death ligand and death receptor concentrations were 
moderate (~ 10 molecules or higher), rapid generation of active caspase 8 molecules led 
to fast deterministic activation of the type 1 pathway and the effect of caspase 6 was to 
slightly reinforce the fast type 1 activation. For low levels of death ligand concentrations 
(~ 2 molecules), caspase 6 mediated feedback loop assisted in enhancing type 1 
activation. For such low death ligand concentrations, especially when death receptor 
concentration is also low, apoptotic activation was dominated by the type 2 pathway with 
large cell-to-cell variability and slow activation of caspase 3; Caspase 6 activation was 
also slow in accordance with slow activation of Caspase 3. Time-course of caspase 6 
activation is provided in Fig. 7b. At the level of single cells, caspase 6 activation was 
prominent only when robust caspase 3 activation was achieved after apoptosome 
formation and caspase 9 activation. Thus Caspase 6 activation led to strong caspase 8 
activation only after capsase 3 activation reached a significant level (at ~ 5 × 107  - 108 
MC steps) (Fig. 7b and 7c). Consistent with our findings, robust activation of both 
caspase 8 and caspase 3 has been shown to be delayed (~ hour) in type 2 cells (Scaffidi et 
al. 1998) (though in those experiments apoptotic activation was probed at the population 
level). In some of our simulations, such as when death ligand ~ 2 molec. and death 
receptor ~ 100 molec., dominant mode of activation was altered from type 2 to type 1 due 
to caspase 6 activation (type 1 fraction: 0.37 ± 0.22 for caspase 6 = 0 and type 1 fraction: 
0.52 ± 32 for caspase 6 = 30 molec.). Thus caspase 6 inhibition can be used as a strategy 
to switch the activation from type 1 to type 2 and to increase cell-to-cell variability. Such 
a strategy can have important ramifications for the recently explored role of caspase 6 
inhibition in treatment of neurodegenerative disorders (Leblanc 2013).   
 
Discussion 
In this work, we elucidate that the concentration of death ligand and the inherent state of 
the membrane proximal signaling module affect the type 1/type 2 choice in apoptotic 
activation. We demonstrate that the inherent state of the membrane proximal module, 
such as the expression level of death receptors, can make cells of a given type prone to 
either type 1 or type 2 activation.  However, concentration of the death ligand also 
emerges to be a key parameter in the type 1/type2 choice. Increased concentration of 
death ligand induction increases type 1 activation and may lead to a type 2 to type 1 
transition in a given cell type. Our results provide a mechanistic understanding of caspase 
6 activation mediated systems level feedback regulation (through caspase 8 activation) 
and its impact on the type 1/type 2 choice. Results obtained in this study also indicate an 
important role of cell-to-cell stochastic variability in caspase 8 activation. Such stochastic 
variability cannot be captured by ODE based models of caspase 8 activation. Majority of 
previous studies exploring the type 1/ type 2 choice in apoptosis did not consider the 
effect of cell-to-cell variability in apoptotic activation. 
In this study, formation of DISC and capsase 8 activation was modeled in a simplified 
manner. Additional complexities might arise from variation in the mode of ligand 
presentation (such as valency) (Huang et al. 1999), explicit simulation of decoy receptors 
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(Pan et al. 1997) and lipid mediated interactions (George and Wu 2012; Song et al. 2007). 
Presentation of oligomeric death ligands might lead to more robust DISC formation and 
induction of type 1 activation in type 2 cells such as hepatocytes (Huang et al. 1999). 
Taken together with our results, strength of death ligand mediated apoptotic stimuli 
seems to be a crucial regulator of the type 1/type 2 choice, irrespective of cell types 
(Raychaudhuri 2010). In this context, it should be noted that membrane bound death 
ligands might be more effective in inducing receptor clustering in the restricted geometry 
of the 2-dimensional cell-cell contact. Lipid mediated interactions have been implicated 
in death ligand induced apoptotic activation even though a complete mechanistic 
understanding is lacking. Some studies indicate that Fas receptors are localized in 
sphingolipid rich regions of the plasma membrane in type 1 cells (Sanlioglu et al. 2005). 
In our current model, clustering of ligand bound death receptors was modeled in an 
effective manner and is governed by a free energy parameter (Edd). Explicit simulation of 
lipid-mediated interactions would allow us to simulate novel strategies to target the 
membrane proximal signaling modules in cancer cells (Gajate and Mollinedo 2011; Song 
et al. 2007; Thome et al. 2012; Xiao et al. 2011; Gulbins and Kolesnick 2003).   
We considered the effect of cell-type specific variations in the membrane module on 
death ligand induced apoptotic activation. However, cell-to-cell variations in the 
expression levels of signaling molecules (such as the level of death receptors (Meng et al. 
2011)) can be significant even within a specific cell type. Such cellular variability may 
arise from epigenetic regulations and stochastic gene expressions. Based on our results it 
can be inferred that cell-to-cell variations in the membrane module for a given cell 
population (of the same type) should also impact the type 1/type 2 choice in apoptotic 
activation. Therefore, even within a cell population of the same type, one cell equipped 
with higher level of death receptor and membrane proximal pro-apoptotic molecules may 
activate the type 1 pathway whereas another cell having lower level of death receptor and 
other pro-apoptotic membrane molecules might exhibit the type 2 signaling phenotype. 
Interestingly, such type 1/type 2 variations at the level of single cells can also result from 
inherent stochastic variability, even when all the cellular parameters (such as the 
concentrations of membrane molecules) remain identical. Cell-to-cell variability in the 
time-to-caspase 8 activation (resulting from inherent stochastic fluctuations), for 
example, can impact the type 1/type 2 choice at the level of single cells. The regulation of 
type 1/ type 2 choice at the level of single cells is an unexpected feature that emerged 
from stochastic Monte Carlo modeling.     
Cell-to-cell stochastic variability has emerged as a key systems level regulatory 
mechanism in type 2 apoptosis. Thus the question of type 1/type 2 choice, in apoptotic 
activation, is frequently linked to the choice between stochastic (large cell-to-cell 
variability) and deterministic activation. In this work, we elucidated that the inherent state 
of membrane proximal signaling module and concentration of death ligand affect cell-to-
cell variability in apoptotic activation. How cell-to-cell variability can be utilized to 
target the apoptotic pathway in treatment of cancer and neurodegenerative disorders 
remains to be explored. In our previous studies, we have explored potential options for 
inducing stochastic to deterministic transition (or at least minimize stochastic variability), 
selectively in cancer cells (Skommer et al. 2011a; Raychaudhuri and Das 2013; 
Raychaudhuri and Raychaudhuri 2013).  It was also indicated that cell-to-cell inherent 
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variability should help protect normal cells during cancer chemotherapy. In a similar 
manner, strategies based on utilization of cell-to-cell variability might be effective in 
protecting cells from apoptosis in neurodegenerative disorders.   
Application of death ligands (such as TRAIL), to induce apoptotic activation in cancer 
cells, has been established as a chemotherapeutic strategy (Picarda et al. 2012; Shirley et 
al. 2011; Kurita et al. 2011). However, one needs to consider how to selectively target 
cancer cells and minimize fractional cell killing. In certain cancer cells, increased 
expression of death receptors and/or decreased amount of decoy receptor can enhance 
susceptibility of the cancer cell’s membrane module to external apoptotic stimuli (Pan et 
al. 1997; Sheridan et al. 1997). Such a mechanism presumably explains selective killing 
of cancer cells observed under TRAIL induction. In addition, vulnerability of the 
membrane module can be selectively induced (or increased) in some types of cancer 
cells, such as by increasing the death receptor expression by genetic mechanisms (Ho et 
al. 2010). However, anti-apoptotic molecules in the membrane proximal signaling 
module, such as cFLIP, are also frequently over-expressed in cancer cells imparting 
apoptosis resistance in those cancer cells (Safa and Pollok 2011). In those cases, selective 
killing of cancer cells can be achieved by simultaneous targeting of a susceptible 
membrane module and inhibition of cFLIP. In this context, recombinant death ligands or 
monoclonal antibodies to death receptors (Picarda et al. 2012), having low affinity for 
death receptors, can be utilized to increase specificity of targeting cancer cells. When we 
simulate apoptotic activation of susceptible cancer cells having increased death receptor 
expression (~ 100 molecules) but no cFLIP (also over-expressed Bcl2 family pro- and 
anti-apoptotic proteins), under the application of small amount of death ligands (~ 2 
molecules) with low affinity (~ 103 M-1 compared to 109 M-1 for typical death ligands), 
rapid type 1 dominant activation was observed (82% cell death in 108 MC steps). In 
contrast, apoptotic activation in a normal cell with lower death receptor expression (~10 
molecules) but significant cFLIP (~ 30 nM) expression was much lower (7% cell death in 
108 MC steps). In addition, the slow activation was dominated by the type 2 pathway 
with large cell-to-cell stochastic variability. There might exist other mechanisms of 
perturbing the susceptible membrane module of the apoptotic pathway, such as by 
combined targeting of death receptors and lipid rafts in a synergistic manner, to induce 
selective activation in cancer cells. Such selective targeting of the cancer cells can be 
achieved if only weak type 2 activation is induced in normal cells (where slow activation 
with large cell-to-cell variability should provide protection).  
Caspase 6 activation has been frequently observed in neural cells undergoing 
degeneration and caspase 6 inhibition is emerging as a promising novel strategy in 
neurodegenerative disorders such as Alzheimer’s disease (Leblanc 2013). In this study of 
death ligand induced apoptosis, we considered systems level feedback regulation 
mediated by active caspase 6. Even if the apoptotic trigger is located in the intrinsic (type 
2) pathway, caspase 6 mediated activation of caspase 8 can start direct processing of pro-
caspase 3 (type 1 activation). Here, we showed how the activation can be switched from 
type 1 to type 2 under caspase 6 inhibition. Such a strategy, based on systems level 
regulatory mechanisms and cell-to-cell stochastic variability, could protect a large 
fraction of cells by minimally perturbing the apoptotic pathway and might turn out to be 
effective under certain situations. How regulation of cell-to-cell variability can be utilized 
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to protect cells in neurodegenerative disorders remains to be explored. Recent studies 
indicated the possibility of caspase 6 self-activation in the context of neurodegenerative 
disorders (Leblanc 2013). However, over-pressed caspase 6 was thought to be required 
(for such self-processing) which would implicate low probability of activation and a role 
of stochastic variability (Raychaudhuri et al. 2008; Raychaudhuri and Das 2013). In silico 
studies, such as the Monte Carlo simulations carried out in this work, can be utilized to 
design optimal strategies for targeting of the apoptotic pathway based on elucidation of 
its systems level regulatory mechanisms. 
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Figures 
 
Figure 1. Schematic of the apoptotic death signaling network. Death ligand induction 
activates apoptosis through two distinct pathways: type 1 (intrinsic) and type 2 
(extrinsic). The type 1-type 2 signaling loop is initiated by generation of active caspase 8 
and ultimately converges on caspase 3/7 activation. Caspase 6 provides a systems level 
feedback activation.   
Figure 2. Type 1 activation fraction (upper panel) and caspase 8 activation (lower panel) 
for increasing death receptor levels. Type 1 activation is estimated when active caspase 3 
concentration reaches 90 nM (90% activation). Death receptor concentration is varied in 
the following manner: 2, 10 and 100 molecules (death ligand concentration is kept fixed 
at 10 molecules). Type 1 activation correlates well with caspase 8 activation at T = 108 
MC steps (lower panel). For caspase 8, activation is normalized to its maximal value (~ 
30 nM). Data is obtained from 60 single cell experiments (Monte Carlo runs).    
Figure 3. (a) Time-course of caspase 3 activation for low death receptor concentration. 
Data is shown for 6 representative (type 2 dominant) cells when DR = 2 molecules. Each 
color corresponds to apoptosis activation for a single cell (Monte Carlo run). (b) Caspase 
3 and caspase 8 activation at a single cell level. Data is shown for 3 representative (type 2 
dominant) cells (DR = 2 molecules). Caspase 8 activation precedes caspase 3 activation 
and contributes cell-to-cell variability in apoptosis activation. (c) Time-to-caspase 8 
activation is correlated to time-to-caspase 3 activation at a single cell level. Time-to-
caspase 8 activation captures the initiation of caspase 8 activation (caspase 8 = 1); Time-
to-caspase 3 activation is for initial (10% of total) caspase 3 activation.  Data is shown for 
60 single cell experiments (Monte Carlo runs). A straight line fit to the data indicates 
high degree of correlation between initiation of caspase 8 activation and early caspase 3 
activation.  
Figure 4. Type 1 activation fraction (upper panel) and caspase 8 activation (lower panel) 
as the membrane proximal signaling module is varied. Simulations were carried out for 
the following parameters: (1) FADD = 10, cFLIP = 10 and procaspase 8 = 10, (2) FADD 
= 100, cFLIP = 100 and procaspase 8 = 100 and (3) FADD = 100, cFLIP = 10 and 
procaspase 8 = 100 (DL = 10 molecules and DR = 10 molecules). Type 1 activation is 
estimated when active caspase 3 concentration reaches 90 nM (90% activation). Type 1 
activation correlates well with caspase 8 activation at T = 5 × 107 MC steps. For caspase 
8, activation is normalized to a value of 30 nM. Data is obtained from 60 single cell 
experiments (Monte Carlo runs).    
Figure 5. Type 1 activation fraction for various death ligand concentrations. Death ligand 
concentration is varied in the following manner: (a) 2 molecules, (b) 10 molecules and (c) 
100 molecules. For each of the death ligand concentration death receptor concentration is 
varied in a similar manner: 2 molecules, 10 molecules and 100 molecules. Type 1 
activation is estimated when active caspase 3 concentration reaches 90 nM (90% 
activation). Data is obtained from 60 single cell experiments (Monte Carlo runs).    
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Figure 6. Time-course of caspase 3 activation for low death ligand concentration. Data is 
shown for 6 representative (type 2 dominant) cells for DL = 2 molecules (DR = 100 
molecules). Each color corresponds to apoptosis activation for a single cell (Monte Carlo 
run). 
Figure 7. (a) Effect of caspase 6 activation on type 1 mode of activation. Type 1 
activation is estimated when active caspase 3 concentration reaches 90 nM (90% 
activation). Data is shown for two different receptor-ligand concentrations: (1) DL=2 
molecules, DR=2 molecules and (2) DL=10 molecules, DR=10 molecules (with and 
without caspase 6; for each receptor-ligand concentration histogram on the right is with 
caspase 6). (b) Activation of caspase 6 as the receptor-ligand concentration is varied. 
Data is shown for three different time-points (T = 5 × 107, T = 1 × 108 and T = 2 × 108 
MC steps) and two different receptor-ligand concentrations: (1) DL=2 molecules, DR=2 
molecules and (2) DL=10 molecules, DR=10 molecules. Activation of caspase 6 is 
normalized to its maximal value (~ 30 nM). Data is obtained from 60 single cell 
experiments (Monte Carlo runs). (c) Activation of caspase 8 (upper panel) and  caspase 3 
(lower panel) with and without caspase 6. Data is shown for three different time-points (T 
= 5 × 107, T = 1 × 108 and T = 2 × 108 MC steps) and two different receptor-ligand 
concentrations: (1) left panel: DL=2 molecules, DR=2 molecules and (2) right panel: 
DL=10 molecules, DR=10 molecules. Activation is normalized to respective maximal 
values (30 nM for caspase 8 and 100 nM for caspase 3). Data is obtained from 60 single 
cell experiments (Monte Carlo runs). 
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Figure 3a. 
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Figure 3c. 
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Figure 4.  
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Figure 5.  
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Figure 7a.  
 
 
Figure 7b.  
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Figure 7c. 
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Supplemental Figure 1. Clustering of death receptors as the energy parameter (for death 
receptor clustering) is varied: (a) Edd = -2 KBT and (b) Edd = -3 KBT. In each case, 2 
representative single cell surfaces are shown for death ligand = 100 molecules (upper 
panel) and 2 molecules (lower panel). Death receptor concentration is kept fixed at 100 
molecules.  (a)	  
	  
	  
 
 0
 60
 0  60
 0
 60
 0  60
 0
 60
 0  60
 0
 60
 0  60
 0
 60
 0  60
 0
 60
 0  60
 0
 60
 0  60
 0
 60
 0  60
(b)	  
